Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic?. (November 2021)
- Record Type:
- Journal Article
- Title:
- Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic?. (November 2021)
- Main Title:
- Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic?
- Authors:
- Gómez-Ayerbe, Cristina
Palacios, Rosario
Ríos, Maria J
Téllez, Francisco
Sayago, Carmen
Martín-Aspas, Andrés
Camacho, Angela
Muñoz, Leopoldo
Santos, Jesús - Abstract:
- Early diagnosis and treatment of incident cases of hepatitis C virus (HCV) infection is fundamental to eliminate HCV in HIV-positive patients. From January 2016 to December 2019, we attended 40 episodes of acute HCV infection (AHC) in 35 subjects (9 reinfections) who were coinfected with HIV. The patients were treated with direct-acting antiviral agents (DAAs) in seven hospitals in Andalusia, Spain. All were men who have sex with men (MSM), mean age was 42.9 (±8.3) years and median time of HIV infection was 46.6 months (IQR: 20.4–67.2). All received antiretroviral therapy and had undetectable HIV viral load (except 2 with 65 and 68 copies/mL); median CD4 count was 632 cells/mm 3 (IQR: 553–896). Over half (74.3%) also had another concomitant sexually transmitted infection, syphilis (48.6%) being the most common. AHC was asymptomatic in 32 cases (80%). Genotypic distribution was G1a 65%, G4 32.5% and G1b 3%. Median time to DAA was 6 weeks (IQR: 4.3–18.3) and median baseline HCV RNA was 6.1 Log (IQR: 5.6–6.5). DAA regimens were SOF/LDV (19 episodes), SOF/VEL (14), ELB/GZV (5) and GLP/PIB (2). All presented sustained viral response and none discontinued due to adverse effects. In conclusion, early treatment with DAA in AHC patients proved effective and safe. It could be an excellent strategy to eliminate HCV infection in HIV-coinfected MSM.
- Is Part Of:
- International journal of STD & AIDS. Volume 32:Number 13(2021)
- Journal:
- International journal of STD & AIDS
- Issue:
- Volume 32:Number 13(2021)
- Issue Display:
- Volume 32, Issue 13 (2021)
- Year:
- 2021
- Volume:
- 32
- Issue:
- 13
- Issue Sort Value:
- 2021-0032-0013-0000
- Page Start:
- 1257
- Page End:
- 1260
- Publication Date:
- 2021-11
- Subjects:
- Antiviral -- MSM -- hepatitis C -- HIV -- sexual behaviour
Sexually transmitted diseases -- Periodicals
AIDS (Disease) -- Periodicals
616.951 - Journal URLs:
- http://std.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/09564624211033756 ↗
- Languages:
- English
- ISSNs:
- 0956-4624
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18256.xml